Form 8-K - Current report:
SEC Accession No. 0001193125-24-002523
Filing Date
2024-01-04
Accepted
2024-01-04 17:00:01
Documents
12
Period of Report
2024-01-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d705253d8k.htm   iXBRL 8-K 25831
  Complete submission text file 0001193125-24-002523.txt   152230

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA howl-20240104.xsd EX-101.SCH 2858
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE howl-20240104_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE howl-20240104_pre.xml EX-101.PRE 11712
6 EXTRACTED XBRL INSTANCE DOCUMENT d705253d8k_htm.xml XML 3470
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 24512981
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)